(sar1)-angiotensin ii

The substitution with Sar at position 1 of angiotensin II resulted in a partial agonistic activity.

[Sar1, Ile8]-Angiotensin II acetate activates both the NADPH and NADH oxidases, and stimulates superoxide anion formation in vascular smooth muscle cells. [Sar1, Ile8]-Angiotensin II acetate has multiple effects on vascular smooth muscle, including contra

[Sar1, Ile8]-Angiotensin II 3TFA ([Sar1, Ile8]-Angiotensin II 3TFA (37827-06-8(free base))) is a peptide that has multiple effects on vascular smooth muscle.

[Sar1, Ile8]-Angiotensin II (TFA) is a peptide compound that affects vascular smooth muscle by causing contraction of normal arteries and inducing hypertrophy or hyperplasia in cultured cells or diseased vessels.

[Sar1, Ile8]-Angiotensin II(3TFA) is a peptide that has multiple effects on vascular smooth muscle.

(Sar1,Ile4,8)-Angiotensin II is a functionally selective agonist for the angiotensin II type 1 receptor (AT1R), enhancing insulin-stimulated signaling of the insulin receptor (IR) and glycogen synthesis, and boosting the insulin-induced phosphorylation of Akt and GSK3α β [1].

Saralasin acetate is a Non-selective angiotensin II antagonist.

Saralasin TFA ([Sar1,Ala8] Angiotensin II) is a synthetic octapeptide analog of angiotensin II, functioning as a competitive antagonist at angiotensin II receptors with a K i value of 0.32 nM for 74% of its binding sites, while also exhibiting partial agonist activity. It is utilized in the study of renovascular and renin-dependent (angiotensinogenic) hypertension [1] [3] [6].